Insufficient development of new antibiotics and the rising resistance of bacteria to those that
we have are putting the world at risk of losing the most widely curative class of medicines …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

“Viable but nonculturable” states of bacteria pose challenges for environmental and clinical
microbiology, but their biological mechanisms remain obscure. Mycobacterium tuberculosis …

The lungs of tuberculosis (TB) patients contain a spectrum of granulomatous lesions,
ranging from solid and well-vascularized cellular granulomas to avascular caseous …

Tuberculosis is a global threat but in particular affects people from developing countries. It is
thought that nearly a third of the population of the world live with its causative bacteria in a …

Despite known treatments, tuberculosis (TB) remains the world's top infectious killer,
highlighting the pressing need for new drug regimens. To prioritize the most efficacious …

The clinical manifestations of tuberculosis (TB) vary widely in severity, site of infection, and
outcomes of treatment—leading to simultaneous efforts to individualize therapy safely and to …

Abstract Persistence of Mycobacterium tuberculosis (Mtb) is one of the challenges to
successful treatment of tuberculosis (TB). In vitro models of non-replicating Mtb are used to …

Mycobacterium tuberculosis (Mtb) is a pathogenic bacterium which causes tuberculosis
(TB). TB control programmes are facing threats from drug resistance. Multidrug-resistant …